

TABLE OF CONTENTS

A. BASIC SCIENCE - SIGNALING PATHWAYS, RECEPTORS, BIOMARKERS

- (A01) Bresciani G et al.** Study of Cell Cycle Protein Expression Pattern in Bronchial Carcinoids: A New Potential Target for Medical Therapy?
- (A02) Briest F et al.** Analysis of Gene Expression Patterns of Rectum Neuroendocrine Tumors (NET) Versus Healthy Tissue Reveals Alterations in the MAPK and WNT Signaling Pathways
- (A03) Briest F et al.** Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine
- (A04) Cella CA et al.** Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus
- (A05) Gantenbein N et al.** Are eIFs Ingredients for Neuroendocrine Tumorigenesis?
- (A06) Grötzinger C et al.** Identification and Validation of the Angiotensin II Receptor Type 1 as a Possible Anti-Cancer Target in Neuroendocrine Tumors
- (A07) Grötzinger C et al.** Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells
- (A08) Gurevich L et al.** Expression of Somatostatin Receptors in Neuroendocrine Tumors of the Lungs with Various Degrees of Malignancy
- (A09) Herrera-Martínez AD et al.** Ghrelin O-Acyltransferase (GOAT) Enzyme and Ghrelin Receptor GHSR1a as Putative Prognosis Markers and Therapeutic Targets in Gastroenteropancreatic Neuroendocrine Tumors
- (A10) Ji M et al.** Long Non-Coding RNA H19 Promotes Malignant Proliferation and Metastasis in Pancreatic Neuroendocrine Neoplasms
- (A11) Milione M et al.** Stromal Immune Contexture Predicts Disease-Free Survival in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs)
- (A12) Na H et al.** Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
- (A13) Napolitano M et al.** IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83
- (A14) Pedraza-Arévalo S et al.** Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells
- (A15) Qiu F et al.** ¹⁷⁷Lu-TOC Inhibits Cell Proliferation by Inducing Autophagy and G2/M Cell Arrest in Neuroendocrine Prostate Cancer Cell
- (A16) Romano D et al.** Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors
- (A17) Sättele R et al.** Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor Expression in Patients with Neuroendocrine Neoplasia

(A18) Tsolakis A et al. Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?

(A19) Vesely C et al. Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumors (NET)

(A20) Vitali E et al. The Anticancer Mechanism of Metformin in Pancreatic Neuroendocrine Tumor Cells

(A21) Zhang Y et al. Expression and Clinical Significance of Vascular Endothelial Growth Factor D in Gastroenteropancreatic Neuroendocrine Neoplasms

(A22) Zhang Y et al. Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms

B. BASIC SCIENCE - GENETICS, EPIGENETICS, MIRNAS, OMICS

(B01) Arvidsson Y et al. miRNA Expression Defines Novel Subgroups of Small Intestinal Neuroendocrine Tumors

(B02) Boons G et al. Genome-Wide DNA Methylation Profiling of Pancreatic Neuroendocrine Tumors

(B03) Capdevila J et al. BRAF-V600E Driven Mutations in Grade 3 Neuroendocrine Carcinomas of Colon Origin: Results from Genomic/Epigenomic Profilings and Patient-Derived Mouse Model

(B04) Cros J et al. Genomic and Transcriptomic Characterization of Aggressive Well Differentiated Pancreatic Neuroendocrine Tumors (WD PanNET)

(B05) Cros J et al. Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies

(B06) Di Domenico A et al. Epigenetic Changes in DAXX and/or ATRX Negative Pancreatic Neuro-Endocrine Tumors

(B07) Fatima A et al. Finding the Ways to Determine the Prognosis of Pulmonary Carcinoids with Certain Genes/Markers in Pakistan

(B08) Hu Y et al. Retrospective Analysis of Gastroenteropancreatic Neuroendocrine Neoplasms and the Role of GSK-3 β Expression in Neuroendocrine Neoplasms

(B09) Jian-an B et al. Analysis of the Proteomics of Serum Circulating Exosomes in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms

(B10) Lawrence B et al. A Novel Classification of Pancreatic Neuroendocrine Tumors (pNETs) Guided by Genomics

(B11) Lin LY et al. Endocan Expression Is Correlated with Poor Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors

(B12) Manoharan J et al. Chemoprevention with Enalapril and Aspirin in Men1(+/-) Knockout Mouse Model

(B13) Pea A et al. Genetic Analysis Identifies Subgroups of Small Well-Differentiated Pancreatic Neuroendocrine Tumors with Different Risk for Liver Metastases

- (B14) Robb T et al.** Enhancing Diagnostic Precision Through Combined Genomic and Histopathological Analysis of Pancreatic Neuroendocrine Tumors
- (B15) Robb T et al.** Merkel Cell Carcinomas in New Zealand: Virus or Ultra Violet?
- (B16) Tirosh A et al.** High Rate of Copy-Number Alterations in Gastrointestinal and Pancreatic Neuroendocrine Tumors with Unidentified Driver Mutations
- (B17) Vandamme T et al.** Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors
- (B18) Wei Y et al.** Screening of Differentially Expressed Genes in Gastric Neuroendocrine Neoplasms Based on Human Transcriptome Array
- (B19) Yang KC et al.** Molecular Characterization of Primary and Metastatic Pancreatic Neuroendocrine Tumors

C. BASIC SCIENCE - IN VITRO MODELS, TUMOR GROWTH, CTCS

- (C01) Blazevic A et al.** The Effect of Temozolomide on Pancreatic Neuroendocrine Tumors in Vitro and Role of MGMT and MMR System in Temozolomide Resistance
- (C02) Briest F et al.** The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents
- (C03) Childs A et al.** Single Cell Copy Number Variation Analysis (CNV) of Circulating Tumor Cells (CTCs) in Neuroendocrine Tumor (NET) Patients
- (C04) Dayton T et al.** Using Adult Stem-Cell Derived Organoids to Model Neuroendocrine Tumor Growth
- (C05) Herrera-Martínez AD et al.** Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture
- (C06) Herrera-Martínez AD et al.** Potential Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumors
- (C07) Hofving T et al.** The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines
- (C08) Martínez-López A et al.** Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition
- (C09) Matrood S et al.** Autophagy Process in Pancreatic Neuroendocrine Tumor Cells
- (C10) Rizzo FM et al.** CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)
- (C11) Sami M et al.** Epigenetic Modulation of Autophagy in Pancreatic Spheroid Cells
- (C12) Schrader J et al.** Development of Pre-Clinical NEN Models – Limitations and Opportunities
- (C13) Sposito T et al.** Histone Replacement in Cancer: Dissecting the Role of H3.3 Chaperones in Pancreatic Tumorigenesis

(C14) Zhang Y et al. Preliminary Evaluation of Influence of Different Targeted Drugs of Vascular Endothelial Growth Factor Signaling Pathway on the Proliferation of Neuroendocrine Neoplasm Cell Lines

D. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - REGISTRIES, NATIONWIDE AND REGIONAL SURVEYS

(D01) Apostolidis L et al. Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)

(D02) Ashoka Menon V et al. Neuroendocrine Tumors: An Australian Experience

(D03) Athar A et al. Recognition of Primary Neuroendocrine Tumors - A Challenge

(D04) Banz S et al. First Patient Survey about Tumor - Associated Fatigue in NEN

(D05) Berthon A et al. Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)

(D06) Berthon A et al. Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden

(D07) Borbath I et al. The ENETS Registry: First Results of a Collaborative Effort Including over 12.000 Patients with Neuroendocrine Neoplasms (NENs) from 7 European Countries

(D08) Cai W et al. Pattern and Risk Factors for Distant Metastases in Gastrointestinal Neuroendocrine Neoplasms: A Population-Based Study

(D09) Carrillo D et al. Neuroendocrine Tumors in the Chilean Population

(D10) Cavalcoli FA et al. Thrombotic Risk in Gastroenteropancreatic Neuroendocrine Tumors: A Single Centre Experience

(D11) Chatzellis E et al. Endocrine Paraneoplastic Syndromes in Patients with Neuroendocrine Neoplasms

(D12) Chiloiro S et al. Diagnostic and Clinical Management of Pancreatic Neuroendocrine in MEN1 Syndrome

(D13) Chiloiro S et al. Screening Benefits in MEN1-Associated Pituitary Adenomas

(D14) Davies P et al. Current Educational Strategies Used by Nurses Caring for NET Patients: Electronic Survey across 25 Countries

(D15) Desai G et al. Trends in Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in India: A Report of Multicentre Data from a Web Based Registry

(D16) El Chami A et al. Single-Institutional Review of Non-Pancreatic GI Neuroendocrine Tumors

(D17) Fan Y et al. Retrospective Analysis of 228 Digestive System Neuroendocrine Tumor Patients from the Northwest of China

- (D18) Fan J et al.** The Trend of Using CT to Diagnose the Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study in China
- (D19) Fatima A et al.** Finding the Options of Good Prognosis for Ampullary Neuroendocrine Tumors
- (D20) Fijalkowski R et al.** Carcinoid Syndrome Open Questions – Evaluations from a Real Life Setting
- (D21) Frizziero M et al.** Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumour Society Centre of Excellence
- (D22) Gaasvik L et al.** Data on Healthcare Resource Utilization (HCRU) and Treatment Modalities in Patients (Pts) with Advanced (adv), Well-Differentiated (WD) Neuroendocrine Tumors (NETs) of Gastrointestinal (GI) or Lung Origin in Finland
- (D23) Galanopoulos M et al.** Reassessment of Risk Factors Associated with Locoregional Lymph Nodal Metastases in Well-Differentiated Appendiceal Neuroendocrine Neoplasms
- (D24) Gao H et al.** Is the Classification of Functioning-PanNET/Non-Functioning PanNET Properly? Insulinoma/Non-Insulinoma Is More Suitable to Distinguish the Clinicopathological and Prognosis Difference of Localized Insulinoma
- (D25) Gao S et al.** The Latest Exploration of Staging and Prognostic Classification for Pancreatic Neuroendocrine Tumors
- (D26) Genc C et al.** Ki67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors
- (D27) Genus T et al.** 1-Year Survival Rates for Neuroendocrine Tumor Patients in England
- (D28) Genus T et al.** Incidence and Prevalence of Neuroendocrine Tumors in England
- (D29) Genus T et al.** Metachronous Primary Cancers in Neuroendocrine Tumor Patients
- (D30) Giannone F et al.** Incidental Histological Diagnosis of Small Pancreatic Neuroendocrine Tumors: Are We Underestimating Their Incidence?
- (D31) Grimaldi F et al.** Vitamin D, Bone Mineral Density and Fracture Risk Assessment in Patients with Neuroendocrine Tumors
- (D32) Hayes AR et al.** Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Characterisation of Prevalence and Prognosis in the Pulmonary Carcinoid Population
- (D33) Issaeva S et al.** Predictive Markers of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
- (D34) Jimenez-Fonseca P et al.** Neuroendocrine Tumors Committee of Reference Hospital: Decision-Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors
- (D35) Khalimova Z et al.** The Results of Screening of the Syndrome of Cushing in the Republic of Uzbekistan

- (D36) Komarova L et al.** Retrospective Epidemiologic Study of Medullary Cancer of Thyroid Gland in Hospital – Based Registry in Moscow Cancer Centre
- (D37) Lal DPCK et al.** Clinical Significance of Incidental Detection of Appendicular Neuroendocrine Tumors in Sri Lanka
- (D38) Li YL et al.** Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: 400 Cases of Multicenter Retrospective Analysis
- (D39) Lim S et al.** Nutritional Assessment and Vitamin Deficiencies in Patients with NETs
- (D40) Liu Z et al.** A Retrospective Analysis of 344 Cases with Neuroendocrine Neoplasms
- (D41) Liu Q et al.** Assessment of Quality of Life in Chinese Patients with Gastroenteropancreatic Neuroendocrine Tumors
- (D42) Lyu Y et al.** Risk Factors Affecting Prognosis in Metachronous Liver Metastases from WHO Classification G1 and G2 Gastroenteropancreatic Neuroendocrine Tumors after Initial R0 Surgical Resection
- (D43) Mao W et al.** Analysis of Clinical Pathology Features and Prognostic Factors of 20 Patients with Appendiceal Neuroendocrine Neoplasms
- (D44) Mao W et al.** Development of a Predictive Prognostic Nomogram for the Neuroendocrine Carcinomas of Rectum Based on a Large Population-Based Exploration
- (D45) Masini G et al.** Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and How?
- (D46) Massironi S et al.** Can Neutrophil-to-Lymphocyte Ratio (NLR) Predict Clinical Outcomes of Pancreatic Neuroendocrine Tumors (PanNETs)?
- (D47) Massironi S et al.** Eterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience in Italy
- (D48) Maurissen I et al.** The Impact of NETwerk on the Multidisciplinary Tumor Boards
- (D49) Mintziras I et al.** Are Current ENETS Guidelines for Surgery of Small (< 2cm) Pancreatic Neuroendocrine Neoplasms Implemented in German Surgical Community?
- (D50) Mintziras I et al.** Perioperative Outcomes of Surgery for Pancreatic Neuroendocrine Neoplasms in Germany
- (D51) Modica R et al.** Survival and Prognosis in Patients with Duodeno-Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome
- (D52) Narimova G et al.** The Condition of Carbohydrate Exchange in New Revealed Patients with Cushing's Syndrome
- (D53) Nayroles G et al.** Prevalence of Carcinoid Syndrome (CS) in the European Union (EU)
- (D54) Parker K et al.** Approaching NETs from Many Angles: A Medical Research Paradigm to Challenge New Zealand's Research Traditions
- (D55) Parker K et al.** The NETwork! Registry Suggests Increasing Incidence in a National Study of Neuroendocrine Cancer in New Zealand (NZ)

- (D56) Qiu XD et al.** Clinicopathological Features of 63 Cases with Type 3 Gastric Neuroendocrine Tumors
- (D57) Reynolds M et al.** Remote Tracking of Symptoms, QoL and Wellbeing within the New Wales NET Service
- (D58) Riechelmann R et al.** High Hepatic Tumor Burden and History of Cardiovascular Comorbidities Are Associated with Carcinoid Heart Disease: A Multicenter and Multinational Study
- (D59) Sarabi M et al.** Patient Survey Devoted to Characterizing Experience and Expectations of Patients with Neuroendocrine Tumors (NET)
- (D60) Sedlackova E et al.** Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) in the Czech NEN Registry 2009-2016: Histologic Spectrum and Clinicopathological Features
- (D61) Stemann Lau T et al.** The Risk of Secondary Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Tumors – A Nationwide Population Based Study
- (D62) Uri I et al.** Diagnosing and Managing MEN1-Related pNETs in Israel: A Specialist Center Experience
- (D63) Urmanova Y et al.** Frequency, the Characteristic of Diseases of Thyroid Gland at Children and Teenagers According to Negotiability during 5 Years
- (D64) Urmanova Y et al.** The Frequency of Patients with Giant Pituitary Tumors from Retrospective Data
- (D65) van Leeuwaarde R et al.** Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?
- (D66) Vandamme T et al.** Excellent Survival Outcomes for NET Patients Treated within NETwerk, a Collaborative ENETS Center of Excellence
- (D67) Vesterinen T et al.** Prognostic Factors of Pulmonary Carcinoid Tumors
- (D68) Whyand T et al.** Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses
- (D69) Winkler EC et al.** Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated "Side Effect" of Cancer in Germany?
- (D70) Wyld D et al.** How the Rare See Their Care: Perceptions of Care and Patient Reported Outcomes in People Living with Neuroendocrine Tumors
- (D71) Yu P et al.** Clinicopathologic Characteristics of Chinese Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study
- (D72) Zandee W et al.** Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers
- (D73) Zhang P et al.** A Single-Center Retrospective Analysis of Clinicopathological Characteristics of Gastroenteropancreatic Large Cell Neuroendocrine Neoplasms (GEP-LCNEC)
- (D74) Zhang P et al.** Clinical Study on High-Risk Factors Leading to Recurrence of Well-Differentiated Pancreatic Neuroendocrine Neoplasms after Surgery
- (D75) Zhang Y et al.** Clinicopathological Features and Prognosis of Colonic Neuroendocrine Neoplasms in Different Races

(D76) Zhang Y et al. The Exact Prognostic Significance of Lymphatic Metastasis of Jejunoileal Neuroendocrine Tumors

E. PATHOLOGY - GRADING, STAGING

(E01) Andreasi V et al. The Number of Positive Nodes Accurately Predicts Recurrence after Pancreaticoduodenectomy for Nonfunctioning Neuroendocrine Neoplasms

(E02) Andreassen M et al. Immunohistochemical Profiles in 81 Patients with Resected Insulinomas

(E03) Boeck I et al. Poorly Differentiated Neuroendocrine Carcinomas of the Colon: A Clinicopathological Study

(E04) Carmona-Bayonas A et al. Expanding the WHO 2017 Classification to Gastrointestinal Tumors: Real-World Data from the R-GETNE Registry

(E05) Delektorskaya V et al. Clinicopathological Features of the High Grade Pancreatic Neuroendocrine Neoplasms

(E06) Dhall D et al. Well-Differentiated Neuroendocrine Lesions in Inflammatory Bowel Disease

(E07) Furnace M et al. High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?

(E08) Gao H et al. Novel Recurrence Risk Stratification of Resected Pancreatic Neuroendocrine Tumor

(E09) Luong TV et al. Phosphohistone H3 (PHH3) Immunohistochemical Staining Outperforms Conventional H&E Mitotic Count in Classifying Pulmonary Carcinoids

(E10) Merola E et al. Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?

(E11) Milione M et al. Ki-67 and Presence of Liver Metastases Predicts Progression in Pancreatic Neuroendocrine Neoplasms (pNENs)

(E12) Rizza S et al. EUS-FNA in the Diagnosis of Pancreatic Neuroendocrine Tumors and Accuracy of Ki-67 Measurement on Cytological Samples: The Turin Experience

(E13) Xu J et al. Intrinsic Contact between T Classification and N Classification in Resected Well-Moderate Differential Locoregional Pancreatic Neuroendocrine Neoplasms

F. BIOMARKERS

(F01) Atanasov G et al. Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors

(F02) Athar A et al. Significance of Biochemical Testing in Pancreatic Neuroendocrine Tumors

(F03) Bajciová V et al. When Is Right Hemicolectomy Really Indicated for Pediatric Appendiceal NETs?

(F04) Chan DL et al. Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

(F05) Dam G et al. A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors

(F06) Genc C et al. The Clinical Value of Circulating Transcript Analysis (NETest) during Follow-Up of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors

(F07) Grigorescu RR et al. Prognostic Value of the Different Pre-Treatment Biomarkers for Patients with Neuroendocrine Tumors

(F08) Kjellman M et al. Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study

(F09) Kruljac I et al. The Role of Subcutaneous Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms: A Pilot Study

(F10) Liu E et al. Assessment of the Clinical Utility of the NETest in a US Registry-Based Study

(F11) Mecca C et al. Tumor Microenvironment in Merkel Cell Carcinoma: Association with Merkel Cell Polyomavirus and Clinico-Pathological Features in a Retrospective Cohort Study

(F12) Moschouris P et al. The Association between Gastrin and Glucose Serum Concentration in Hypergastrinemic Patients with Gastric Neuroendocrine Tumors Type 1 and ECL-Cells Hyperplasia

(F13) Partelli S et al. Circulating Neuroendocrine Gene Transcripts (NETest) Decrease Early after Radical Surgery: Preliminary Results of a Prospective Study

(F14) Rosiek V et al. Assessment of the Serum Levels of the Soluble Vascular Cellular Adhesion Molecule-1 (sVCAM-1) in Patients with Neuroendocrine Neoplasms

(F15) Rossi RE et al. Alpha-Fetoprotein in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Single Centre Study

(F16) Rossi RE et al. Chromogranin A as a Marker in the Follow-up of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). A Systematic Review

(F17) Sadanandam A et al. Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

(F18) Tirosch A et al. 24 Hour Urinary 5-Hydroxyindoleacetic Acid Levels in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors

(F19) Vladova P et al. Prognostic Value of Immunohistochemical Expression of Somatostatin Receptors (SS-R2 and SS-R5) in the Gastroenteropancreatic Neuroendocrine Tumors, Diagnosed in the University Hospital of Pleven, Bulgaria, from the Period 2010 to November 2017

G. IMAGING AND INTERVENTIONS (RADIOLOGY, ENDOSCOPY)

(G01) Antwi A et al. Comparison of Glucagon-Like-Peptide-1 (GLP-1) Receptor PET/CT, SPECT/CT and 3T MRI for the Localisation of Insulinomas: Evaluation of Accuracy in a Prospective Crossover Imaging Study

- (G02) Blazevic A et al.** Progression of Mesenteric Metastasis in Small Intestinal Neuroendocrine Tumors
- (G03) Carmona-Bayonas A et al.** Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)
- (G04) Chiloiro S et al.** 99mTc-Colloid Scintigraphy in the Differential Diagnosis of Pancreatic NET
- (G05) Crona J et al.** Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study
- (G06) Fehrenbach U et al.** How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms
- (G07) Gao S et al.** Transcatheter Arterial Chemoembolization Synergizes with Simultaneous Microwave Ablation in the Treatment of Unresectable Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastasis
- (G08) Gulati S et al.** Linked Colour Imaging Increases the Diagnostic Yield of Type 1 Gastric Carcinoid
- (G09) Iorio J et al.** Imaging Modality Depending on the Levels of Tumor Markers
- (G10) Janas K et al.** 4D Ultrasound High Definition Flow with Spatio-Temporal Image Correlation in Evaluation of Neuroendocrine Liver Metastases – Preliminary Study
- (G11) Kieszko D et al.** CT-Guided HDR Brachytherapy in Patients with Advanced Non-Resectable and Progressive NEN with Liver Bulky Disease. Pilot Study
- (G12) Lamarca A et al.** Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study
- (G13) Liu Y et al.** Hepatic Tumor Burden Can Be Reduced Rapidly and Effectively by Trans-Arterial Embolization Combined with Systemic Therapy in Patients with Neuroendocrine Tumor Liver Metastasis (NETLM)
- (G14) Michałowska I et al.** Carcinoid Heart Disease - Diagnostic Usefulness of Cardiac Computed Tomography – A Pilot Study
- (G15) Ronot M et al.** Mechanisms of Main Pancreatic Duct Dilatation in Pancreatic Neuroendocrine Tumors (PanNETs): Radiopathologic Correlation
- (G16) Thiis-Evensen E et al.** The RECIST Criteria Compared to Conventional Response Evaluation after Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasms
- (G17) Tsoi M et al.** The Role of Magnetic Resonance Imaging and Endoscopic Ultrasound Imaging in the Diagnosis and Management of Pancreatic Neuroendocrine Tumors (pNET) in Patients with Multiple Endocrine Neoplasia Type 1 (MEN1)

H. MEDICAL TREATMENT - CHEMOTHERAPY SOMATOSTATIN ANALOGUES, INTERFERON

- (H01) Ali AA et al.** Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
- (H02) Antonijoan Arbós RM et al.** Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers
- (H03) Capdevila J et al.** Prospective, Multi-Center, Open Label, Phase Study II of APOC, a New Controlled Release 15mg Octreotide Acetate, for the Treatment of Advanced NETs
- (H04) Ćwikła JB et al.** Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)
- (H05) Dal Buono A et al.** Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens
- (H06) Daskalakis K et al.** Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
- (H07) Davies P et al.** Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)
- (H08) De Divitiis C et al.** Efficacy and Toxicity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
- (H09) Faggiano A et al.** Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study
- (H10) Geldenhuys D et al.** Interim Analyses LANREL07484: Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa
- (H11) Geldenhuys D et al.** Interim Analyses LANREL07484: Response to Treatment and Self-Reported Satisfaction in Symptoms in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa
- (H12) Giuffrida D et al.** Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis
- (H13) Ichikawa Y et al.** Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy
- (H14) Klink A et al.** A Comparison of Retrospective Database Analysis with Chart Review in Patients Receiving Somatostatin Analog (SSA) in Neuroendocrine Tumors (NETs)
- (H15) Kolasińska-Ćwikła A et al.** Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)

- (H16) Lamarca A et al.** International Survey of Clinical Practice Exploring Use of Platinum-Etoposide Chemotherapy for Extra-Pulmonary High Grade Neuroendocrine Carcinoma (EP-G3-NEC)
- (H17) Laskaratos F et al.** Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)
- (H18) Laskaratos F et al.** Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs)
- (H19) Pavel M et al.** Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study
- (H20) Pellat A et al.** Perioperative Chemotherapy in Resectable Neuroendocrine Carcinomas of the Digestive Tract
- (H21) Puliafito I et al.** Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience
- (H22) Sakamoto Y et al.** Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan
- (H23) Smiroldo V et al.** Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (Captem) in Patients with Metastatic Neuroendocrine Tumors (NETS). A Single-Institution Experience
- (H24) Wang X et al.** Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors
- (H25) Zhang Y et al.** Capecitabine/Temozolomide (CAPTEM) Regimen in the Treatment of Advanced Neuroendocrine Neoplasms: A Single-Center Retrospective Study in China

I. MEDICAL TREATMENT - TARGETED THERAPIES

- (I01) Dasari A et al.** A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors
- (I02) Fatima A et al.** Do We Need Hormonal Therapy for Pancreatic Neuroendocrine Tumors? An Effort to Reduce the Size of PanNETs
- (I03) Fazio N et al.** Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
- (I04) Fejzibegovic N et al.** Activity of Bevacizumab in Neuroendocrine Neoplasms
- (I05) Jennifer C et al.** Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors
- (I06) Jimenez-Fonseca P et al.** Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
- (I07) Kuznetsova A et al.** Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors

(I08) Lombard-Bohas C et al. OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

(I09) Rinzivillo M et al. Sunitinib in Patients with Pre-Treated Pancreatic Neuroendocrine Tumors: A Real-World Study

(I10) Yao JC et al. ElevatioN:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

J. MEDICAL TREATMENT - OTHERS, NOT SPECIFIED

(J01) Al-Toubah T et al. Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors

(J02) Bei X et al. Clinical Characteristics and Prognostic Analysis of 14 Patients with Gastric Mixed Adenoneuroendocrine Carcinoma

(J03) Bongiovanni A et al. Metastatic Neuroendocrine Neoplasia Treatments in over 70 Years Old Patients: A Retrospective Outcome Analysis

(J04) Byakhova M et al. The Role of Diagnostic Biopsy to Determine the Treatment Tactics of Patients with Lung Tumors of Different Histogenesis. The Experience of a Single Multidisciplinary Center for the Period 2014-2017 Years

(J05) Custodio A et al. On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs): RECOSY Study Design

(J06) Dillon J et al. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

(J07) Fatima A et al. Identifying the Severity of Psychosocial Symptoms among Patients Diagnosed with Pancreatic Neuroendocrine Tumor. Do We Really Need Emotional Support Groups?

(J08) Gallego J et al. Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study

(J09) Gueguen D et al. OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design

(J10) Hernando J et al. Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial/GETNE 1601)

(J11) Ivanov A et al. Clinical and Morphological Features of Extrapulmonary Small-Cell Cancer

(J12) Jia R et al. Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplasms

- (J13) Kaiser K et al.** Patient and Clinician Perspectives on Symptom Priorities across the Spectrum of Neuroendocrine Tumors (NETs)
- (J14) Kennedy E et al.** Exploring Nutrition Screening and Management Practices amongst Health Professionals Managing Patients with Neuroendocrine Tumors
- (J15) Kennedy E et al.** Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study
- (J16) Khan M et al.** Development of a Patient-Centred Service for Neuroendocrine Tumors (NETs) in Wales: Population Based National Commissioning
- (J17) Kieseewetter B et al.** Oral Ondansetron Offers Effective Symptomatic Bridging for Carcinoid Syndrome Refractory to Somatostatin Analogues
- (J18) Pevny S et al.** Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status
- (J19) Safarova M et al.** Menstrual Dysfunction in Women with Prolactinomas
- (J20) van Veenendaal LM et al.** Safety and Efficacy of TAE and SIRT in NET Patients

K. NUCLEAR MEDICINE - IMAGING AND THERAPY (PRRT)

- (K01) Aalbersberg E et al.** Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with NETs
- (K02) Aalbersberg E et al.** Parameters to Predict Overall Survival after PRRT – A Multivariate Analysis in 783 Patients
- (K03) Bodei L et al.** Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker
- (K04) Braat A et al.** International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors
- (K05) de Mestier L et al.** Detection of Bone Metastases at FDOPA-PET in Small-Intestine (si)NET: Prevalence and Associated Factors
- (K06) Dureja S et al.** 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience
- (K07) Huizing D et al.** Short-Term Change in Symptoms and Adverse Events Evaluation after PRRT – First Experience after 56 Patients
- (K08) Kolasinska Cwikla A et al.** PRRT in Hindgut and Cancer of Unknown Primary NEN
- (K09) Kong G et al.** Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)
- (K10) Konsek SJ et al.** Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest
- (K11) Ladwa R et al.** Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)

- (K12) Ladwa R et al.** Pretherapeutic Predictors of Tumor Absorbed Dosimetry in Radionuclide Therapy for Metastatic Neuroendocrine Tumors
- (K13) Ladwa R et al.** Tumor Absorbed Dosimetry and Response of Radionuclide Therapy in Metastatic Neuroendocrine Tumor
- (K14) Liotsou T et al.** Diagnostic Utility of ki67 as a Mean to Predict the Uptake of Functional Imaging Modalities in Patients with Neuroendocrine Neoplasms
- (K15) Liotsou T et al.** Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity
- (K16) Mailman J et al.** Education and Preparation for Nuclear Medicine Procedures in Neuroendocrine Tumor Patients
- (K17) Majala S et al.** Nonfunctional Pancreatic Neuroendocrine Tumor (NF PNET) Imaging and Evaluation Using 18F-FDG and 68Ga- DOTANOC- PET/CT: Initial Data of a Prospective Study
- (K18) Picallo M et al.** One Year Experience with Lutetium-DOTATATE for Disseminated NETs in the Gregorio Marañón Hospital
- (K19) Rottenburger C et al.** Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study
- (K20) Skovgaard D et al.** Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study
- (K21) Steyn R et al.** Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study
- (K22) Strosberg J et al.** Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors
- (K23) van der Zwan W et al.** A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine
- (K24) van der Zwan W et al.** PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort
- (K25) Virgolini I et al.** Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NETs
- (K26) Yan SX et al.** Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yttrium-90 PET Scan
- (K27) Yordanova A et al.** Efficacy of Adding Somatostatin Analogues to [177Lu] Lu-Octreotate as a Combination and Maintenance Therapy in Metastatic Neuroendocrine Tumors
- (K28) Yu J et al.** The Correlation between 68Ga-DOTATATE PET/CT Results and Tumor Proliferation in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

L. SURGICAL TREATMENT AND ABLATIVE THERAPIES

(L01) Blazevic A et al. Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors

(L02) Brighi N et al. Morphological Factors Related to Nodal Metastases in Neuroendocrine Neoplasms of the Appendix. A Multicenter Retrospective Study

(L03) Clift AK et al. Appropriate Surgical Strategy in Appendiceal Neuroendocrine Tumors: Is Right Hemicolectomy Oncologically Justified or Overtreatment?

(L04) Dai H et al. The Prognostic Impact of Primary Tumor Resection in Pancreatic Neuroendocrine Tumors with Synchronous Multifocal Liver Metastases

(L05) Holmager P et al. Neuroendocrine Neoplasms of the Appendix: Characterization of 251 Patients Referred to the Copenhagen NET Centre of Excellence

(L06) Malpaga A et al. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Non Functioning Pancreatic Neuroendocrine Tumors: Outcome Analysis from 378 Consecutive Resections in a High-Volume Institution

(L07) Mao W et al. A Matched-Pair Analysis of Conventional Surgical Methods versus Enucleation for Pancreatic Neuroendocrine Tumors

(L08) Marchegiani G et al. The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-Trend and Outcome Analysis from 587 Consecutive Resections at a High-Volume Institution

(L09) Masui T et al. A Comparison of Recurrence after Curative Resection between Pancreatic and Duodenal Neuroendocrine Tumors

(L10) Milanetto AC et al. 35 Years of Experience in a Single Center on Distal Pancreatectomy for Neuroendocrine Tumors

(L11) Milanetto AC et al. Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors

(L12) Milanetto AC et al. Pancreatic Involvement in Small Intestinal Neuroendocrine Tumors

(L13) Milanetto AC et al. Pancreatic NET or Pancreatic Clear Cell Renal Cancer Metastases in Post-Nephrectomy Patients?

(L14) Milanetto AC et al. Pancreatic NETs with Liver Metastases. Outcome of Surgically Treated Patients. A Single Center Experience

(L15) Milanetto AC et al. Survival after Surgical Treatment of Small Intestinal Neuroendocrine Tumors with Liver or Peritoneal Metastases: 25 Years of Experience

(L16) Muffatti F et al. Tumor Size Correlates with Grading in Nonfunctioning Pancreatic Neuroendocrine Tumors and Is Not Age-Dependent

(L17) Piccioli AN et al. Predicting Resectability of Primary Tumor and Mesenteric Lumps in Patients with Small Intestine Neuroendocrine Tumors

(L18) Ruzzenente A et al. Liver Resection for Neuroendocrine Tumors Liver Metastases in Transplantable Patients within the Milan Criteria

(L19) Zubaryev M et al. The Laparoscopic Approach in the Surgical Treatment of the Gastric Neuroendocrine Tumors

M. NON DIGESTIVE NETS (BRONCHIAL, THYMIC, OTHERS) - DIAGNOSIS AND THERAPY

(M01) Apostolidis L et al. Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma

(M02) Barlow J et al. Pulmonary Function Test Physiology and Progression in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia

(M03) Castillo-Fernandez O et al. Primary Neuroendocrine Tumors of the Breast

(M04) Groendahl V et al. Results of 252 Patients with Bronchopulmonary Neuroendocrine Tumors Treated at the Copenhagen NET Centre of Excellence

(M05) Kasajima A et al. PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung

(M06) Li Q et al. Clinicopathologic Features and Treatment Outcome of 225 Newly Diagnosed Pulmonary Carcinoids: A Single Center Experience of 28 Years

(M07) Martins Branco D et al. Large Cell Neuroendocrine Carcinoma of the Lung: Single-Centre Retrospective Cohort Study

(M08) McFadyen R et al. Typical and Atypical Bronchial NETs with Advanced Disease: Incidence, Management and Survival

(M09) Modlin I et al. Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors

(M10) Talbot D et al. A Comparison of Diagnostic and Management Pathways for Patients with Lung Neuroendocrine Tumors in ENETS Centres of Excellence vs Non-Accredited Centres in the UK: Results from the National Lung NET Pathway Project ('LEAP')

N. ENDOCRINE MALIGNANCIES (MTC, PHEOCHROMOCYTOMA) - DIAGNOSIS AND THERAPY

(N01) Cai W et al. Clinical and Pathological Differences between NEC and Carcinoma of Esophagus: A Population Based Study

(N02) Loh WJ et al. Sensitivity and Specificity of Insulin, C-peptide and Nadir Glucose during 72 hr Supervised Fast in Diagnosis of Insulinoma

(N03) Mansfield A et al. Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

(N04) Muñoz de Nova JL et al. Early Prognostic Factors in Medullary Thyroid Carcinoma

(N05) Soczomski P et al. Pancreatic Neuroendocrine Tumor in Polish Population with MEN 1 Syndrome

(N06) Zhang Y et al. Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma